Under Development

Below is the list of biopharmaceuticals being developed by Bionovis together with Janssen and Merck and the biological products fully developed by Bionovis in-house:

Trastuzumab:

Trasuzumab is indicated for the treatment of initial breast cancer, metastatic breast cancer and advanced gastric cancer.

Bevacizumab:

Bevacizumab is indicated for the treatment of metastatic colorectal cancer, non-squamous non-small cell lung cancer, metastatic renal cell carcinoma and metastatic breast cancer.

Etanercept:

Etanercept is indicated for the treatment of autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis.

Rituximab:

Rituximab is indicated for the treatment of non-Hodgkin lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia and granulomatosis with Polyangiitis.

Adalimumab:

Adalimumab is indicated for the treatment of autoimmune diseases such as Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis.

BNV-003:

Biological medicine indicated for the treatment of colorectal cancer and squamous cell carcinoma of head and neck.

BNV-004:

Biological medicine indicated for the treatment of multiple sclerosis.

BNV-005 (in-house development):

Biological medicine indicated for the treatment of autoimmune diseases.

BNV-006 (in-house development):

Biological medicine indicated for the treatment of autoimmune diseases.